BioCryst Pharmaceuticals is a commercial-stage biotech developing oral small-molecule and injectable protein therapeutics for rare diseases, including hereditary angioedema (HAE) and complement-mediated diseases.
BioCryst Pharmaceuticals has been on a journey this year. | BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.